Whalestein Group

Explore the Whalestein Ecosystem

Our dedicated platforms support existing investors and internal research. The Investor Portal provides portfolio performance, investment records and account information, while Sonar Intelligence brings together company research, financial analysis and supporting evidence for authorised research users.

Kioxia: Patent litigation and the investment outlook

Research on Kioxia’s patent litigation and its implications for the company’s investment outlook.

Kioxia market-note graphic comparing the share-price decline with operating performance and risks.
Kioxia market-note graphic comparing the share-price decline with operating performance and risks. Original publication graphic.View full-size graphic

$Kioxia just crashed nearly 60%.

But here’s the strange part.
The business didn’t.

So, what actually happened?

At first glance, you’d think Kioxia had a terrible quarter.

Reality?
📈 Revenue +37% YoY
📈 Net profit +104% YoY
📈 EBITDA margin above 50%

Those aren’t numbers from a company falling apart.

Instead, the selloff came from 4 different events happening almost at once.

1. Lost a $229M patent lawsuit
– A real hit. Kioxia was ordered to pay Viasat in a U.S. court.

2. Samsung’s selloff spilled over
– Samsung dropped after regulatory changes in South Korea.
– Investors sold memory stocks across Asia. Kioxia got caught in the wave.

3. OpenAI IPO rumors
– Reports that OpenAI could delay its IPO triggered another sharp selloff.

The surprising part?
Kioxia has no direct business relationship with OpenAI.

4. Japan tech de-risking
– Before earnings, investors sold Japanese AI names across the board:
~SoftBank.
~Tokyo Electron.
~Advantest.
~Kioxia.

It became a sector-wide selloff, not just a Kioxia story.

Public references

Company materials for further reference. Directories change over time; this note retains its original date, views and figures.

This publication reflects its original publication date. Research and commentary are provided for information and do not constitute investment advice.

All market insights